Amatoxin Antibody-Drug Conjugates for Selective Stem Cell Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates (ADCs) face challenges in achieving both efficacy and tolerability, particularly in targeted delivery to cancer cells and stem cell depletion, with existing toxins causing unacceptable toxicity to normal cells and tissues.
Innovation Solution
Development of amatoxin-based ADCs with specific antibodies, such as those binding to PSMA, Her2, CD37, or CD123, conjugated via linkers, including mutations like L234A, L235A, and D265C, to enhance targeting and minimize side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing toxins are used in ADCs for targeted delivery to cancer cells, then cytotoxic efficacy against tumor cells is achieved, but unacceptable toxicity to normal cells and tissues occurs
Solution Approach 1:
The patent applies local quality by engineering the antibody with specific mutations (L234A, L235A, D265C) that create cysteine residues at defined locations in the Fc region. This allows site-specific conjugation of the toxin to particular locations on the antibody, ensuring the cytotoxic agent is delivered precisely to target cells while minimizing off-target effects. The localized modification at specific amino acid positions enables controlled toxin attachment that maintains both efficacy and reduced systemic toxicity.
Solution Approach 2:
The patent employs parameter changes by modifying the antibody's Fc region through specific point mutations that alter its biochemical properties. The L234A, L235A, and D265C mutations change the antibody's structure to introduce free cysteine thiols, which then serve as conjugation sites for the toxin. This parameter modification transforms the antibody into a platform that can carry and deliver the cytotoxin selectively, resolving the contradiction between achieving sufficient cytotoxicity and minimizing damage to normal cells.
2Reliability
If ADCs are designed for stem cell depletion to prepare patients for transplant, then engraftment of donor cells is enabled, but patient side effects increase with existing toxins
Solution Approach 1:
The patent applies local quality by introducing specific mutations (L234A, L235A, D265C) at defined locations in the antibody Fc region. These localized structural changes create specific conjugation sites that enable precise toxin attachment, allowing selective depletion of stem cells for transplant preparation while minimizing collateral damage to other cell types and reducing overall patient side effects.
3Reliability
If antibodies are conjugated to cytotoxic agents to form ADCs, then therapeutic efficacy is increased, but tolerability decreases due to cytotoxin impact
Solution Approach 1:
The patent applies local quality by engineering the antibody with site-specific mutations (L234A, L235A, D265C) that create controlled conjugation sites. This localized modification approach ensures the cytotoxic agent is attached at specific positions on the antibody, optimizing the balance between maintaining therapeutic efficacy and reducing tolerability issues. The precise localization of the toxin enhances targeted delivery while minimizing off-target toxicity.
Solution Approach 2:
The patent employs parameter changes by modifying the antibody's Fc region through specific point mutations that alter its structure and conjugation properties. The L234A, L235A, and D265C mutations transform the antibody into an optimized ADC platform, enabling controlled toxin attachment that maintains high therapeutic efficacy while improving patient tolerability by reducing systemic cytotoxin exposure.
Data Source
AI summary
Amatoxins, as well as antibody-drug conjugates (ADCs) and compositions have amatoxin and can be used for cancer therapy, to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions treat various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases and prevent graft-versus-host disease (GVHD).